Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ASLAN Pharmaceuticals Ltd. (ASLN : NSDQ)
 
 • Company Description   
ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore.

Number of Employees: 27

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.46 Daily Weekly Monthly
20 Day Moving Average: 208,174 shares
Shares Outstanding: 69.75 (millions)
Market Capitalization: $32.29 (millions)
Beta: 2.33
52 Week High: $3.87
52 Week Low: $0.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -38.67% -32.81%
12 Week -48.56% -44.18%
Year To Date -58.66% -50.84%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
83 CLEMENCEAU AVENUE NO 12-03 UE SQUARE
-
SINGAPORE,U0 239920
SGP
ph: 65-6222-4235
fax: 65-6225-2419
investor@aslanpharma.com https://aslanpharma.com
 
 • General Corporate Information   
Officers
Carl Firth - Chief Executive Officer and Director
Andrew Howden - Chairman
Kiran Asarpota - Chief Operating Officer and Head of Finance
Stephen Doyle - Chief Business Officer
Robert E. Hoffman - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04522R101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 69.75
Most Recent Split Date: (:1)
Beta: 2.33
Market Capitalization: $32.29 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.66 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.72
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -46.15%
vs. Previous Quarter: -18.75%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -58.72
12/31/21 - -42.37
09/30/21 - -49.32
ROA
03/31/22 - -37.34
12/31/21 - -30.02
09/30/21 - -33.11
Current Ratio
03/31/22 - 9.63
12/31/21 - 14.75
09/30/21 - 16.60
Quick Ratio
03/31/22 - 9.63
12/31/21 - 14.75
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.65
12/31/21 - 0.82
09/30/21 - 1.79
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.81
12/31/21 - 0.54
09/30/21 - 0.45
Debt-to-Capital
03/31/22 - 44.69
12/31/21 - 35.00
09/30/21 - 31.17
 

Powered by Zacks Investment Research ©